Research
Energy balance
Semaglutide is the most cost-effective treatment option in the severe obesity patient population and in first-tier cities in China.
In specific urban populations with severe obesity, semaglutide may be a preferred treatment option.
StrongSupportsmedium confidence
Scenario analysis showed that, in the severe obesity patient population and in first-tier cities in China, semaglutide is the most cost-effective treatment option.
Why this rating
Based on scenario analysis within the cost-effectiveness framework.
Source
Cost‐effectiveness analysis of four glucagon‐like peptide‐1 or glucose‐dependent insulinotropic polypeptide/glucagon‐like peptide‐1 receptor agonists for the treatment of adult patients with overweight and obesity in China
Wu Fu et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16581
Meta-analysisCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- None of the four glucagon-like peptide-1 receptor agonist (GLP-1RA) or glucose-dependent insulinotropic polypeptide (GIP)/GLP-1RA therapies were cost-effective compared with lifestyle management.Strong
- Lifestyle management was the most likely to be cost-effective under the willingness-to-pay threshold.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →